Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furmonertinib versus placebo after complete resection with or without adjuvant chemotherapy in EGFR-mutant stage IA2 high-risk to IIIA NSCLC
CTR20210429Phase 3Active
- Sponsor
- Allist Pharmaceuticals
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of furmonertinib in non-small cell lung cancer (NSCLC), sponsored by Allist Pharmaceuticals. Started Jun 2021; status: active.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20210429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210429.